Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.

ABSTRACT:

SUBMITTER: Chatterjee A 

PROVIDER: S-EPMC10391182 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature